B+
Bull case
20%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-02-09 · RankAlpha Sentiment AI
NVST
EnvistaCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$24.54
Analysis reference price unavailable
Analysis 2026-02-09 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$14.22
Analysis reference price unavailable
Analysis 2026-02-09 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-09
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+54.0
Score
AI commentary
Sentiment is mixed-to-cautious: the consensus median is below the broker_last anchor while a few brokers maintain $30+ targets. Near-term direction will hinge on the upcoming quarterly report and post-earnings analyst reactions; longer-term conviction depends on product execution and consumables growth.
RankAlpha Sentiment AI - 2026-02-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-10catalystNext quarterly earnings report (estimated)High impact
Quarterly earnings and management guidance are the most likely near-term re-rating events; analysts' consensus targets imply downside vs the broker_last anchor which could drive revision risk after results [#SERP-2]. Date follows conservative short-horizon estimate per schema rules.
2026-06-09eventPost-earnings analyst target revisionsHigh impact
Broker and sell-side target changes (e.g., recent Baird update) commonly arrive after reported results and can alter sentiment materially; assume revisions materialize within ~30 days of results [#SERP-9].
2027-02-09catalystProduct pipeline execution and market-share recoveryHigh impact
Sustained upside would require successful commercialization of product initiatives and recovery in dental procedure volumes; this is a multiyear driver that aligns with surveyed analyst upside but depends on execution [#SERP-6].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-09 • Updated nightlySource: Internal modelMethodology